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The most common complication of pregnancy is diabetes. It 
is estimated that one in six pregnancies are affected (16.6%), 
with 84% of diabetic pregnancies being affected by gesta-
tional diabetes mellitus (GDM).1 More than 15  years ago, 
the evidence was clear that treatment of even mild GDM had 
beneficial effects on both maternal and neonatal outcomes.2 
These findings were instrumental in encouraging clinicians 
to offer detection and intervention for GDM. The evidence 
is also accumulating linking maternal GDM with future 
disorders of maternal glucose metabolism and of increased 
childhood adiposity.3,4 Identifying women with GDM is thus 
important for the health of the mother and infant in the index 
pregnancy but also for their future health to prevent non- 
communicable diseases.
The Hyperglycaemia and Adverse Pregnancy Outcomes 
study was a blinded observational study of 23,316 women 
from 15 centres in nine countries across five continents 
tested for glucose tolerance at 24– 32  weeks. A continuous 
positive relationship was found between the fasting, 1- and 
2- h glucose measurements and birth weight >90th percen-
tile, cord C- peptide >90th percentile and percentage body fat 
>90th percentile.5 The IADPSG criteria for GDM screening 
were calculated based on an adjusted odds ratio of 1.75 for 
these events.6 These criteria are supported for use by many 
organizations including the WHO,7 American Diabetes 
Association,8 International Federation of Gynaecology and 
Obstetrics, European Board and College of Obstetrics and 
Gynaecology, European Association for Perinatal Medicine, 
Australasian Diabetes in Pregnancy Society and International 
Diabetes Federation. The WHO recommends a one- step ap-
proach to screening as women with a positive glucose chal-
lenge test frequently do not attend for a glucose tolerance test. 
In addition, a GDM diagnosis is based on one abnormal value 
in contrast to two abnormal values required by the Carpenter 
and Coustan (CC) criteria. There is considerable evidence in 
the literature that when using the latter test, one abnormal 
value on the test confers an increased risk of adverse preg-
nancy outcomes when compared to a test where all values are 
normal. Nevertheless, considerable controversies remain for 
GDM diagnosis with some countries advising use of National 
Institute of Health and Care Excellence criteria or CC crite-
ria9 while others such as India and Canada devising their own 
population- based criteria.
The International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) community was interested to read 
the recently conducted large pragmatic randomized con-
trolled trial (RCT) by Hillier and colleagues of GDM screen-
ing, comparing a one- step approach using IADPSG criteria 
to a two- step approach using CC criteria. We congratulate 
the authors on this large pragmatic trial in a high- risk pop-
ulation and acknowledge the efforts required to complete 
such a trial. The trial concluded that there were no signifi-
cant differences between approaches in the risks of the pri-
mary perinatal and maternal outcomes but importantly with 
a smaller proportion of women diagnosed as GDM.10 We 
welcome additional RCTs in the field and note that this is 
the first large RCT to randomize between these strategies. 
Nevertheless, the results may be difficult to interpret and 
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raise some questions: First, many women (33%) failed to 
proceed with their randomized one- step approach. The ran-
domization component of an RCT is done in order to con-
trol for unmeasured variables and reduce bias. The authors 
acknowledge that this difference in randomization was not 
random, with different characteristics in patients/providers 
opting in and out of assigned randomization.11 This may 
have influenced the final trial outcome. If provider bias 
was present at randomization, could it also have influenced 
treatment— particularly in those who fulfilled one- step but 
not the two- step approach? Second, first- trimester screening 
of obese and ‘high- risk’ women was implemented with over 
3000 women in each study arm screened.11 Agreement on 
whether or how risk for GDM can be diagnosed in first- 
trimester GDM is lacking12 and this questions whether in-
clusion of this group may have influenced trial findings. 
Taken together we wonder whether, in a field where provid-
ers may hold strong views on the efficacy of one or other 
approach, blinding, as far as possible, would have been 
necessary to eliminate these possible biases. Finally, there 
was no black representation in this trial and just 15%– 16% 
Medicaid recipients.
Another recently published article is also critical of cur-
rent screening practices and argues that an international 
multicentre trial of treatment rather than screening is war-
ranted using IADPSG criteria as a basis for patient selec-
tion.13 The authors suggest that the trial should incorporate 
cost- benefit, cost- effectiveness and cost- utility analyses. We 
believe that with the correct trial design including blinding 
to eliminate bias, many questions regarding screening, 
treatment benefits and long- term maternal and offspring 
health could be examined simultaneously. In design of such 
studies, randomizing patients away from usual practice is 
often seen as an ethical issue. However, given the variety 
of practices internationally and the equipoise that exists we 
believe such blinded studies will be the only way to move 
forward. In addition, new technologies such as continuous 
glucose monitoring could be included to examine a more 
user- friendly approach to screening and a biobank could be 
incorporated to explore alternative biomarkers for GDM di-
agnosis. It would be important for the future applicability 
of any proposed trial that participants are multi- institutional 
and multinational. With the launch of the Horizon Europe 
Health Programme, now is the time to work collectively to 
design and deliver such a trial to address unanswered ques-
tions around GDM.
The IADPSG's interest in GDM has long been in promot-
ing evidence- based practice for detection of metabolic dis-
ease in pregnancy. Ironically, while the controversy around 
criteria has raged, there has been worsening of underlying 
metabolic health in the pregnant population as measured in 
prevalent type 2 diabetes, newly discovered type 2 diabetes 
and obesity during pregnancy. Add to this the concerns over 
intergenerational effects of maternal hyperglycaemia. Thus, 
there is no debate on the urgency of the problem. Promoting 
women's health in preparation for and during pregnancy 
should be our priority. This includes screening for and treat-
ing GDM. Rather than procrastinating further, let us work 
together to find the solutions.
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